Lanthanum Viatris

Lanthanum, the active ingredient in Lanthanum Viatris, is a phosphate binder presented as an unknown/unknown for oral use. It treats hyperphosphatemia in patients with chronic kidney disease. GNH USA supplies Lanthanum Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Lanthanum Viatris is a phosphate binder used to manage elevated serum phosphate in chronic kidney disease and related conditions.

- Chronic kidney disease with hyperphosphatemia: lowers serum phosphate levels to within target range. - Patients on dialysis with hyperphosphatemia: helps control phosphate load from diet and dialysis. - Renal transplant recipients with hyperphosphatemia: assists in maintaining phosphate balance while preserving graft function.

Lanthanum may cause a range of adverse reactions, most of which are related to the gastrointestinal tract.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Constipation: reduced bowel movements, sometimes requiring dietary adjustment. - Abdominal discomfort: cramping or pain in the stomach area. - Flatulence: increased gas production.

Serious or Rare Side Effects: - Severe constipation leading to bowel obstruction: may require medical intervention. - Allergic reactions: rash, itching, or swelling of the face, lips, or tongue. - Hypercalcemia: elevated calcium levels, especially when used with calcium-containing products. - Gastrointestinal bleeding: rare but potentially serious bleeding in the digestive tract.

When prescribing Lanthanum, clinicians should consider several safety measures to minimize risks. - Monitor serum phosphate: adjust dose based on regular laboratory testing. - Assess calcium balance: avoid concurrent high calcium intake that may cause hypercalcemia. - Evaluate gastrointestinal health: patients with a history of bowel obstruction should use with caution. - Adjust for renal function: dose may need modification in severe kidney impairment. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Store at below 25°C: keep in the original pack, protect from moisture.

Lanthanum can affect the absorption of other orally administered medicines, requiring attention to timing and monitoring.

Major Interactions (Avoid): - Iron supplements: may bind to lanthanum, reducing its phosphate‑binding efficacy. - Tetracycline antibiotics: lanthanum can decrease absorption, lowering antibiotic effectiveness. - Levothyroxine: concurrent use may reduce thyroid hormone uptake.

Moderate Interactions (Monitor Closely): - Vitamin D analogues: combined effect on calcium and phosphate balance should be monitored. - Calcium carbonate: additive phosphate binding may increase risk of hypercalcemia. - ACE inhibitors: monitor serum potassium and renal function when used together.